Key points are not available for this paper at this time.
The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.
Share your take
Add a clinician perspective alongside expert commentary.
Peyrin‐Biroulet et al. (2024) studied this question.